Adeno-associated Virus (AAV) Serotype 9 Provides Global Cardiac Gene Transfer Superior to AAV1, AAV6, AAV7, and AAV8 in the Mouse and Rat

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2008 Sep 18

PMID 18795839

Citations 153

Authors

Lawrence T Bish

Kevin Morine

Meg M Sleeper

Julio Sanmiguel

Di Wu

Guangping Gao

James M Wilson

H Lee Sweeney

Affiliations

Soon will be listed here.

Abstract

Heart disease is the leading cause of morbidity and mortality. Cardiac gene transfer may serve as a novel therapeutic approach. This investigation was undertaken to compare cardiac tropisms of adeno-associated virus (AAV) serotypes 1, 6, 7, 8, and 9. Neonatal mice were injected with 2.5 x 10(11) genome copies (GC) of AAV serotype 1, 6, 7, 8, or 9 expressing LacZ under the control of the constitutive chicken beta-actin promoter with cytomegalovirus enhancer promoter via intrapericardial injection and monitored for up to 1 year. Adult rats were injected with 5 x 10(11) GC of the AAV vectors via direct cardiac injection and monitored for 1 month. Cardiac distribution of LacZ expression was assessed by X-Gal histochemistry, and beta-galactosidase activity was quantified in a chemiluminescence assay. Cardiac functional data and biodistribution data were also collected in the rat. AAV9 provided global cardiac gene transfer stable for up to 1 year that was superior to other serotypes. LacZ expression was relatively cardiac specific, and cardiac function was unaffected by gene transfer. AAV9 provides high-level, stable expression in the mouse and rat heart and may provide a simple alternative to the creation of cardiac-specific transgenic mice. AAV9 should be used in rodent cardiac studies and may be the vector of choice for clinical trials of cardiac gene transfer.

Citing Articles

Genetic tracing and topography of spontaneous and stimulated cardiac regeneration in mice.

Secco I, Backovic A, Tomczyk M, Mura A, Li G, Bortolotti F Nat Cardiovasc Res. 2025; .

PMID: 40055464 DOI: 10.1038/s44161-025-00623-3.

Genotype-phenotype insights of pediatric dilated cardiomyopathy.

Dai Y, Wang Y, Fan Y, Han B Front Pediatr. 2025; 13:1505830.

PMID: 39959410 PMC: 11825472. DOI: 10.3389/fped.2025.1505830.

CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis.

Gu B, Li M, Li D, Huang K J Cardiovasc Transl Res. 2025; .

PMID: 39804565 DOI: 10.1007/s12265-024-10587-7.

Targeted Bmal1 restoration in muscle prolongs lifespan with systemic health effects in aging model.

Gutierrez-Monreal M, Wolff C, Rijos E, Viggars M, Douglas C, Pagala V JCI Insight. 2024; 9(22).

PMID: 39352748 PMC: 11601919. DOI: 10.1172/jci.insight.174007.

Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment.

Yao B, Lei Z, Goncalves M, Sluijter J Curr Cardiol Rep. 2024; 26(11):1197-1208.

PMID: 39259489 PMC: 11538137. DOI: 10.1007/s11886-024-02118-2.

References

Choi V, Samulski R, McCarty D . Effects of adeno-associated virus DNA hairpin structure on recombination. J Virol. 2005; 79(11):6801-7. PMC: 1112146. DOI: 10.1128/JVI.79.11.6801-6807.2005. View

Du L, Kido M, Lee D, Rabinowitz J, Samulski R, Jamieson S . Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther. 2004; 10(3):604-8. DOI: 10.1016/j.ymthe.2004.06.110. View

Bostick B, Ghosh A, Yue Y, Long C, Duan D . Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 2007; 14(22):1605-9. DOI: 10.1038/sj.gt.3303029. View

Pacak C, Mah C, Thattaliyath B, Conlon T, Lewis M, Cloutier D . Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 2006; 99(4):e3-9. DOI: 10.1161/01.RES.0000237661.18885.f6. View

McCarty D, Fu H, Monahan P, Toulson C, Naik P, Samulski R . Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 2003; 10(26):2112-8. DOI: 10.1038/sj.gt.3302134. View

Andino L, Takeda M, Kasahara H, Jakymiw A, Byrne B, Lewin A . AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes. J Gene Med. 2007; 10(2):132-42. DOI: 10.1002/jgm.1131. View

Gao G, Alvira M, Wang L, Calcedo R, Johnston J, Wilson J . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002; 99(18):11854-9. PMC: 129358. DOI: 10.1073/pnas.182412299. View

Zhang J, Woo Y, Chen J, Swain J, Sweeney H . Efficient transmural cardiac gene transfer by intrapericardial injection in neonatal mice. J Mol Cell Cardiol. 1999; 31(4):721-32. DOI: 10.1006/jmcc.1998.0905. View

Godecke A . AAV vector re-targeting: A small step on the way to cardiac-specific gene transfer. Cardiovasc Res. 2006; 70(1):6-8. DOI: 10.1016/j.cardiores.2006.02.013. View

10.

Inagaki K, Fuess S, Storm T, Gibson G, McTiernan C, Kay M . Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther. 2006; 14(1):45-53. PMC: 1564441. DOI: 10.1016/j.ymthe.2006.03.014. View

11.

Gao G, Vandenberghe L, Alvira M, Lu Y, Calcedo R, Zhou X . Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004; 78(12):6381-8. PMC: 416542. DOI: 10.1128/JVI.78.12.6381-6388.2004. View

12.

Palomeque J, Chemaly E, Colosi P, Wellman J, Zhou S, Del Monte F . Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther. 2007; 14(13):989-97. DOI: 10.1038/sj.gt.3302895. View

13.

Carter B . Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol Ther. 2004; 10(6):981-9. DOI: 10.1016/j.ymthe.2004.09.011. View

14.

Pleger S, Most P, Boucher M, Soltys S, Chuprun J, Pleger W . Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007; 115(19):2506-15. DOI: 10.1161/CIRCULATIONAHA.106.671701. View

15.

Muller O, Leuchs B, Pleger S, Grimm D, Franz W, Katus H . Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res. 2006; 70(1):70-8. DOI: 10.1016/j.cardiores.2005.12.017. View

16.

Hajjar R, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A . Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008; 14(5):355-67. DOI: 10.1016/j.cardfail.2008.02.005. View

17.

Muller O, Katus H, Bekeredjian R . Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res. 2006; 73(3):453-62. DOI: 10.1016/j.cardiores.2006.09.021. View

18.

Zincarelli C, Soltys S, Rengo G, Rabinowitz J . Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008; 16(6):1073-80. DOI: 10.1038/mt.2008.76. View

19.

Woo Y, Zhang J, Taylor M, Cohen J, Hsu V, Sweeney H . One year transgene expression with adeno-associated virus cardiac gene transfer. Int J Cardiol. 2005; 100(3):421-6. DOI: 10.1016/j.ijcard.2004.09.003. View

20.

McCarty D, Monahan P, Samulski R . Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001; 8(16):1248-54. DOI: 10.1038/sj.gt.3301514. View